Audit: QRS - Topical Retinol for Skin Rejuvenation
Audit conducted on 13/08/2026 14:53 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span against the ER: protocol values (ER 303, 307, 309, 315), time-to-effect (ER 341, 162, 166), tier lists (ER 148–192, 209–253), gates (ER 267–286), monitoring table (ER 365–372) and cadence (ER 363). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | marker_5_target retains “No established target for retinol users”; speculative tiers are carried as “Speculative” in both Benefits and Risks. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Pregnancy stays in Contraindications (line 542), matching the ER’s “Populations who should avoid” list; oral isotretinoin remains an absolute contraindication rather than a caution. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come only from the ER “Populations who should avoid” block, Key Interactions only from the ER interaction bullets; no Benefit- or Risk-Modifying Factor content appears anywhere on the sheet. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | Source scan returns no PubMed links, no “et al.”, no NCT identifiers and no brand names. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No named investigators, institutions or organisations appear in any populated span. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, non-promotional register; British spellings (“colour”, “remodelling”, “photodegradation”) carried over from the ER. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Numeric anchors (concentrations, week markers, biomarker ranges) sit alongside plain-language framing in At-A-Glance and Qualitative Assessment. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is presented as labelled facts (“Standard regimen”, “Concentration ceiling”) rather than instructions issued to a patient. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No prescriptive verbs; the Protocol panel reports the standard regimen and the Monitoring cadence reports review timing without directing anyone. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | The ER’s “Practitioners typically start…” and “Ongoing review is best set at…” are rendered as declarative data (lines 447–450, 673), not as recommendations. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the source. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are limited to ER-verbatim benefit, risk and biomarker names required by items 12.x, 13.x and 14.x. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every populated span is a single short phrase or one- to two-clause sentence. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by the same second-person scan; the Qualitative Assessment items are phrased as observations, not instructions. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | The sheet assumes willingness to run baseline serum retinol, fasting retinyl esters, ALT and DXA-derived T-score. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | The staged twelve-week titration schedule and the standardised-photography efficacy endpoint both assume sustained effort. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Biomarker targets are functional ranges, not conventional laboratory cut-offs, which is not general-population framing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Aggregate vitamin A exposure is surfaced as a Medium risk and as three separate gate items, reflecting an audience already taking supplements. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The string “anti-aging” does not occur in the file; the framing term is “Skin Rejuvenation”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “Retinoid dermatitis”, “transepidermal water loss”, “mottled hyperpigmentation” and “re-epithelialisation”-level register throughout; At-A-Glance plain language is mandated separately by item 7.4. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All present and unmodified: lines 440, 477, 519, 574, 593, 679 (cards), 539, 553 (gates), 522–531 and 577–586 (tiers), 597–599 (table headers). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | 58 data-qrs-var spans present, covering the full variable set the checklist addresses (header ×4, at_a_glance, action_1–3 ×3, time_1–3 ×3, four benefit tiers, stop/caution, four risk tiers, marker_1–6 ×3, monitoring_cadence, qualitative_item_1–6). |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The three non-variable spans (website=”evidence_review”, website=”audit”, website=”full_review”) remain untouched at lines 423, 426 and 434. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section feeding the QRS is empty; every benefit tier, risk tier, gate list, protocol, monitoring and qualitative source block is populated. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Standard regimen”, “Best time of day” and “Concentration ceiling” match ER lines 303, 307 and 315 verbatim; the nine Key Interactions labels match ER lines 267–276. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Benefit and risk names match the ER headings word for word; biomarker names match the ER table’s Biomarker column exactly. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Source scan returns no emoji code points; the ER’s 🟩/🟥/🟨 tier markers and the ⚠️ Conflicted flags were correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Single .sheet container with the template’s A4 @page rule intact; content was condensed rather than extended (e.g., marker_5_target trimmed from the ER’s longer phrasing, parenthetical glosses dropped from the gate items). |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14: the comment opens on line 2, immediately after the doctype on line 1, and precedes every other comment and the head. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” on line 3, closing “—” on line 13; the descriptive text on line 2 sits before the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment and not duplicated in the header, footer or any card. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:02" is quoted, and it contains a colon; all other values are bare and untrimmed of nothing. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: topical_retinol_skin_2026-0813-1321_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5 states 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0813-1442. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version number, no context-window or tier qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the file’s own name on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all ten keys; no stray whitespace and no unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Topical Retinol for Skin Rejuvenation - Quick Reference Sheet”; the canonical topic contains no characters requiring entity encoding. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417 matches ER frontmatter canonical_topic exactly. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “08/13/2026”, the correct reformatting of 2026-0813-1442. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”, identical to the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header holds only the title and the template subline; the ER’s “Also known as” list (Retinol, all-trans-retinol, Vitamin A1, Vitamin A Alcohol) was correctly omitted. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Line 433 compresses all three Conclusion paragraphs’ decision-relevant content: what it is, the benefit ranking, the dominant drawback, and the open pregnancy question. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 56 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | “convert, inefficiently … gentler … weaker” (ER 396); “softening of fine lines is the strongest” plus pigment and structure (ER 396); “redness, flaking … main reason people stop” (ER 398); pregnancy (ER 398). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | Uses “vitamin A”, “prescription creams”, “fine lines”, “patchy colour”, “skin structure”, “redness and flaking” — no acronyms and no clinical-register vocabulary. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No investigator names, years, cohort sizes or p-values appear. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | The ER’s 44%, 84%, 1.64-point and odds-ratio figures are all absent. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All seven items map one-to-one onto the ER “Populations who should avoid Topical Retinol” block (ER 278–286) inside that section. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Lines 542–548 reproduce all seven ER entries in ER order, with no additions and no omissions. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Seven discrete <li> elements inside the span at lines 541–549. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | No dashes introduce trailing clauses; no rationale, citation or study detail appears in any of the seven items. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “particularly the first trimester”, “one month after the course ends”, “two to four weeks”, “Child-Pugh Class B or C” and “above 10% of total circulating vitamin A” are all retained; only the two plain-language glosses were trimmed, leaving the staging and threshold intact. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s contraindication list uses no ranking notation inside parentheses. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names seven such populations, and the section is correspondingly populated. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine items map onto the ER interaction bullets at lines 267–276. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Nine of the ER’s ten interaction bullets appear; “Oral isotretinoin” is correctly excluded because it is an absolute contraindication already carried in [stop_items]. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Nine discrete <li> elements inside the span at lines 555–565. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every ER bullet’s post-colon rationale (washout periods, sunscreen mitigation, morning/evening separation, the 3000 µg ceiling) is stripped; only the labels remain. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All named example lists survive: tretinoin/tazarotene/adapalene; doxycycline/hydrochlorothiazide/amiodarone; hydrocortisone/triamcinolone/mometasone; glycolic/lactic/salicylic; L-ascorbic acid; and the five procedures, which the ER offset with an em-dash and the QRS normalised into parentheses. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s interaction bullets use no ranking notation inside parentheses. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names ten interactions, and the section is correspondingly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells trace to the ER “Therapeutic Protocol” section (lines 303, 307, 309, 315). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Starting concentration and titration schedule, timing/frequency, and the concentration ceiling are the three decision-bearing choices; the competing-approach and origins bullets are correctly not surfaced as actions. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies well over three actionable aspects, and all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | Nine populated spans at lines 444–472; “0.1–0.3% at night” (ER 303), “Night, single application” (ER 307/309) and “0.3%” (ER 315). |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Fine wrinkle reduction, mottled hyperpigmentation improvement and matrix remodelling — the three benefits for which the ER states a timeline. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered High (Fine Wrinkle Reduction) then the two Medium benefits, matching the ER’s tiering at lines 148, 156 and 164. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects are present in the ER and all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | “12 weeks” and its sub from ER 341; “12–52 weeks” and its sub from ER 162; “4 weeks” and its sub from ER 166 and 341. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER supplies an explicit “Time to effect” bullet (line 341) plus per-benefit timelines, so the section is retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All seven entries come from ER lines 148–192. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated at lines 521–532. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the bare ER heading; the ER’s Magnitude paragraphs (1.64 points, 44%, 84%, 1.5-fold) are entirely absent. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | The ER’s benefit headings carry no parentheticals; the “⚠️ Conflicted” flag on Fine Wrinkle Reduction is correctly dropped per item 4.4. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers carry at least one ER benefit, so no span needed hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All seven entries come from ER lines 209–253. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated at lines 576–587. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the bare ER heading; the 5% withdrawal rate, 4% absorption figure and the pregnancy odds ratios are all absent. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | The ER’s risk headings carry no parentheticals; the “⚠️ Conflicted” flag on First-Trimester Pregnancy Exposure is correctly dropped per item 4.4. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers carry at least one ER risk, so no span needed hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | The table reproduces the ER “Monitoring Protocol & Defining Success” biomarker table (ER 365–372). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All six ER rows present: Serum Retinol, Fasting Serum Retinyl Esters, ALT, Bone Mineral Density (T-score), Transepidermal Water Loss, Graded Crow’s-Foot Score — with targets and rationales matching the ER’s Optimal Functional Range and Why Measure It? columns. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Line 673 reproduces the ER’s week 2 / week 4 / week 12 / 6-month / 12-month schedule (ER 363). |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All six items come from the ER’s “Qualitative markers worth tracking” list (ER 376–381). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | Six ER markers, six QRS items, reproduced verbatim at lines 682–698: stinging/burning, visible flaking, morning tightness, makeup/sunscreen behaviour, subjective smoothness, sun sensitivity. |
Issues 13/08/2026 14:53
Pass rate 100.00%. No issues found.
Issues 13/08/2026 14:47
- 2.5 / 2.6 / 2.9 — Imperative in protocol sub-cell:
action_1_sub(line 450) ends with the bare imperative “reassess at twelve weeks”, which instructs the reader rather than presenting information; the ER states it descriptively as “reassessing at twelve weeks” (ER line 303).
Fixes 13/08/2026 14:47
- 2.5 / 2.6 / 2.9 — Imperative in protocol sub-cell: Changed
action_1_subfrom “then nightly as tolerated; reassess at twelve weeks.” to “then nightly as tolerated, with reassessment at twelve weeks.”, removing the direct instruction to the reader.